DE10111040A1 - Use of combinations of alpha-lipoic acid and ultraviolet absorbers for treating inflammatory skin disorders or protecting sensitive dry skin - Google Patents

Abstract

Combinations of alpha -lipoic acid (I) and one or more ultraviolet (UV-A or UV-B) absorbers (II) are used for the prophylaxis or treatment of inflammatory skin disorders or for protecting sensitive dry skin.

Description

The present invention relates to the use of combinations of active ingredients α-lipoic acid and dermatologically compatible substances that absorb light in UV-A Range and / or UV-B range, for the production of cosmetic or dermato logical preparations for the prophylaxis and treatment of inflammatory skin conditions and / or for skin protection in sensitive, determined dry skin.

The invention further relates to the use of such active substances and preparations, such Containing active ingredients for immune stimulation of the skin, advantageously also for immune stimulation mulation in the sense of a treatment of the injured skin, in particular for the treatment of Wounds.

Furthermore, the invention relates to preparations with extremely low so-called "Stinging potential".

The skin, especially the epidermis, is the barrier organ of the human organism subject to a particular degree to external influences. According to today's knowledge scientific understanding, the skin represents an immunological organ that is considered immune competent peripheral compartment has its own role in inductive, effective and regu latent immune processes of the whole organism plays.  

The epidermis is rich with nerves and nerve endings like Father Pacini Lamellar bodies, Merkel-cell neurite complexes and free nerve endings for Pain, cold, warmth and itching.

Immunosuppression in general is the suppression or weakening of the reactions vity of the immune system. Immunosuppression can have local and systemic effects be broken down. Ultimately, it includes a variety of different aspects, which all involve a reduction in the normal immunological defense mechanisms of the skin th.

For people with sensitive, sensitive or vulnerable skin, using "stinging" (<engl. <"to sting" = injure, burn, pain) designated neurosensory phae nouns are observed. This "sensitive skin" differs fundamentally from "tro skin "with thickened and hardened horny layers.

Typical reactions of "stinging" to sensitive skin are reddening, tension and burning the skin as well as itching.

The itching in atopic skin is to be regarded as a neurosensory phenomenon, as well Itching with skin diseases.

"Stinging" phenomena can be regarded as disorders to be treated cosmetically the. On the other hand, severe itching, especially severe itching of the skin, can also be called a more serious dermatological disorder.

Typical associated with the terms "stinging" or "sensitive skin" disturbing neurosensory phenomena are reddening of the skin, tingling, tingling, tension and Burning skin and itching. You can by stimulating environmental conditions z. B. massage, surfactant, weather like sun, cold, dryness, but also moist heat, heat radiation and UV radiation, e.g. B. the sun, who caused the.

In "Journal of the Society of Cosmetic Chemists" 28, pp. 197-209 (May 1977) P. J. Frosch and A. M. Kligman a method for estimating the "stinging potential" to  administered substances. As positive substances z. B. lactic acid and Pyruvic acid used. When measured using this method, however, Ami Nonacids, especially glycine, determined to be neurosensory active (such substances are called "Stinger").

According to previous knowledge, such sensitivity to be quite attuned substances individually differently. This means a person who is at Experienced contact with a substance "stinging effects", it is very likely experience repeatedly with every further contact. Contact with other "stingers" can but just as well go without any reaction.

Many more or less sensitive people also have some when using de preparations having a soda or antiperspirant effect under erythematous skin symptoms to suffer.

Erythematous skin symptoms also appear as side effects in certain Skin disorders or irregularities. For example, the typical skin is blow with the appearance of acne regularly more or less reddened.

It was therefore the object of the present invention, the disadvantages of the prior art Remedy technology.

In particular, active substances and preparations containing such active substances should metallic and dermatological treatment and / or prophylaxis of erythematous, ent inflammatory, allergic or autoimmune reactive symptoms, especially dermatos sen, but also of the appearance of the "stinging".

Furthermore, such active substances or preparations containing such active substances should be used Are made available, which are also used for immune stimulation of the skin who uses immunostimulation in the sense of the wound-promoting effect that can.

According to the invention, the drawbacks of the prior art are eliminated by using active substance combinations

• a) α-lipoic acid and
• b) one or more dermatologically compatible substances that absorb light in the UV-A range and / or UV-B range

for the prophylaxis and treatment of inflammatory skin conditions - including the atopic Eczema - and / or for skin protection in sensitive, determined dry skin.

When using the active ingredient combinations or cosmetics used according to the invention shear or topical dermatological preparations with an effective content of inventions Active ingredient combinations used in accordance with the invention is effective in a synergistic manner me treatment, but also a prophylaxis of inflammatory skin conditions - also that atopic eczema - and / or for skin protection in sensitive, determined dry skin possible. The active ingredient according to the invention or cosmetic or topical dermato logical preparations with an effective content of active ingredient according to the invention but also surprisingly serves to calm sensitive or irritated Skin.

The active substance combinations according to the invention act sy in all these uses energetic in relation to the individual components.

α-Lipoic acid was isolated from liver tissue in 1952 and its structure as sulfur-containing Fatty acid cleared up. Bacteria, plants and higher organisms can be found in α-lipoic acid manufacture their metabolism themselves, for humans the question of their own bio synthesis still open.

α-Lipoic acid is used to treat polyneuropathy, a sensitivity disorder on the hands and feet used as a late consequence of diabetes. 200 to 600 milligrams of α-lipoic acid per Day lead to a significant reduction in pain intensity. The energy substance Alternation of the hand and foot nerves is activated by α-lipoic acid, which is why better nerve conductivity and thus less numbness and reflexes cases.

α-Lipoic acid lowers pathologically increased liver values and promotes the healing of the hepati tis. Most foods contain small amounts of α-lipoic acid, only in  Meat can be found at relatively high levels. It is recognized that α-lipoic acid is strong has oxidative properties.

WO 97/10808 and US Pat. No. 5,472,698 describe the cosmetic use of α-lipoic acid against symptoms of aging. DE 42 42 876 describes active ingredient Combinations of biotin and antioxidants with α-lipoic acid for cosmetic and / or dermatological care of the skin and / or skin appendages and cosmetic and / or dermatological preparations containing such active ingredient combinations.

The preparations according to the invention advantageously contain 0.001-10% by weight of α- Lipoic acid, based on the total weight of the preparations.

The preparations according to the invention contain substances which UV radiation in the UV-A and / or absorb UV-B range, the total amount of filter substances z. B. 0.1% by weight to 30% by weight, preferably 0.5 to 20% by weight, in particular 1.0 to 15.0% by weight, based on the total weight of the preparations, is cosmetic To provide preparations that cover the hair or skin before the whole Protect the area of ultraviolet radiation. You can also use it as a sunscreen Serving hair or skin.

Advantageous UV-A filter substances in the sense of the present invention are dibenzoyl methane derivatives, especially the 4- (tert-butyl) -4'-methoxydibenzoylmethane (CAS no. 70356-09-1), which is sold by Givaudan under the Parsol® 1789 brand and by Merck under the Trade name Eusolex © 9020 is sold.

Further advantageous UV-A filter substances are phenylene-1,4-bis (2-benzimidazyl) -3,3'- 5,5'-tetrasulfonic acid

and their salts, especially the corresponding sodium, potassium or triethanolamium salts, in particular the phenylene-1,4-bis (2-benzimidazyl) -3,3'-5,5'-tetrasulfonic acid-bis-sodium salt

with the INCI name Bisimidazylate, which, for example, under the Handelsbe drawing Neo Heliopan AP is available from Haarmann & Reimer.

Also advantageous are the 1,4-di (2-oxo-10-sulfo-3-bornylidenemethyl) benzene and its salts (especially the corresponding 10-sulfato compounds, especially the corresponding sodium, potassium or triethanolammonium salt ), which is also called benzene-1,4-di (2-oxo-3-bornylidenemethyl-10-sulfonic acid) and is characterized by the following structure:

Advantageous UV filter substances in the sense of the present invention are also so-called called broadband filters, d. H. Filter substances that contain both UV-A and UV-B radiation absorb.

Advantageous broadband filters or UV-B filter substances are, for example, bis-resorcinyl triazine derivatives with the following structure:

wherein R ¹ , R ² and R ^{3 are} independently selected from the group of ver branched and unbranched alkyl groups having 1 to 10 carbon atoms or a single hydrogen atom. Particularly preferred are the 2,4-bis - {[4- (2-ethylhexyloxy) -2-hydroxy] phenyl} -6- (4-methoxyphenyl) -1,3,5-triazine (INCI: Aniso triazine) , which is available under the trade name Tinosorb® S from CIBA-Chemicals GmbH, and the 4,4 ', 4 "- (1,3,5-triazine-2,4,6-triyltriimino) -tris-benzoic acid -tris (2-ethylhexyl ester), synonymous: 2,4,6-tris- [anilino- (p-carbo-2'-ethyl-1'-hexyloxy)] - 1,3,5-triazine (INCI: octyl Triazone), which is sold by BASF Aktiengesellschaft under the trade name UVINUL® T 150.

Also other UV filter substances, which the structural motif

have, are advantageous UV filter substances in the sense of the present invention, for example the s-triazine derivatives described in European patent application EP 570 838 A1, the chemical structure of which by the generic formula

is reproduced, whereby
R represents a branched or unbranched C ₁ -C ₁₈ alkyl radical, a C ₅ -C ₁₂ cycloalkyl radical, optionally substituted by one or more C ₁ -C ₄ alkyl groups,
X represents an oxygen atom or an NH group,
R _{1 is} a branched or unbranched C ₁ -C ₁₈ alkyl radical, a C ₅ -C ₁₂ cycloalkyl radical, optionally substituted with one or more C ₁ -C ₄ alkyl groups, or a hydrogen atom, an alkali metal atom, an ammonium group or a group of formula

means in which
A represents a branched or unbranched C ₁ -C ₁₈ alkyl radical, a C ₅ -C ₁₂ cycloalkyl or aryl radical, optionally substituted by one or more C ₁ -C ₄ alkyl groups,
R _{3 represents} a hydrogen atom or a methyl group,
n represents a number from 1 to 10,
R _{2 represents} a branched or unbranched C ₁ -C ₁₈ alkyl radical, a C ₅ -C ₁₂ cycloalkyl radical, optionally substituted by one or more C ₁ -C ₄ alkyl groups,
when X represents the NH group, and
a branched or unbranched C ₁ -C ₁₈ alkyl radical, a C ₅ -C ₁₂ cycloalkyl radical, optionally substituted with one or more C ₁ -C ₄ alkyl groups, or a hydrogen atom, an alkali metal atom, an ammonium group or a group of the formula

means in which
A represents a branched or unbranched C ₁ -C ₁₈ alkyl radical, a C ₅ -C ₁₂ cycloalkyl or aryl radical, optionally substituted by one or more C ₁ -C ₄ alkyl groups,
R _{3 represents} a hydrogen atom or a methyl group,
n represents a number from 1 to 10,
when X represents an oxygen atom.

A particularly advantageous UV filter substance in the sense of the present invention is also an asymmetrically substituted s-triazine, the chemical structure of which is represented by the formula

is reproduced, which is also called dioctylbutylamidotriazon (INCI: Dioc tylbutamidotriazone) and under the trade name UVASORB HEB is available from Sigma 3 V.  

The European patent application 775 698 also describes bis-resorcinyltriazine derivatives which are to be used advantageously and whose chemical structure is represented by the generic formula

is reproduced, wherein R ₁ , R ₂ and A _{1 represent a} wide variety of organic radicals.

Also advantageous in the sense of the present invention are the 2,4-bis - {(4- (3-sulfonato) -2- hydroxypropyloxy) -2-hydroxy] phenyl} -6- (4-methoxyphenyl) -1,3,5-triazine sodium salt, the 2,4-bis - {[4- (3- (2-propyloxy) -2-hydroxy-propyloxy) -2-hydroxy] phenyl} -6- (4-methoxyphenyl) - 1,3,5-triazine, the 2,4-bis - {[4- (2-ethylhexyloxy) -2-hydroxy] phenyl} -6- [4- (2-methoxyethyl carboxyl) phenylamino] -1,3,5-triazine, the 2,4-bis - {[4- (3- (2-propyloxy) -2-hydroxypropyloxy) - 2-hydroxy] phenyl} -6- [4- (2-ethylcarboxyl) phenylamino] -1,3,5-triazine, the 2,4-bis - {[4- (2- ethyl-hexyloxy) -2-hydroxy] phenyl} -6- (1-methyl-pyrrol-2-yl) -1,3,5-triazine, the 2,4-bis - {[4- tris (trimethylsiloxysilylpropyloxy) -2-hydroxy] phenyl} -6- (4-methoxyphenyl) -1,3,5-triazine, the 2,4-bis - {[4- (2 "-methylpropenyloxy) -2-hydroxy] phenyl} -6- (4-methoxyphenyl) -1,3,5-triazine and the 2,4-bis - {[4- (1 ', 1', 1 ', 3', 5 ', 5', 5'-heptamethylsiloxy-2 "-methyl-propyloxy) -2-hydroxy-phenyl- 6- (4-methoxyphenyl) -1,3,5-triazine.

An advantageous broadband filter for the purposes of the present invention is 2,2'-methylene-bis- (6- (2H-benzotriazol-2-yl) -4- (1,1,3,3-tetramethylbutyl) phenol) [INCI : Bisoctyltriazole], which by the chemical structural formula

is marked and under the trade name Tinosorb® M at CIBA Chemical GmbH is available.

Another advantageous broadband filter for the purposes of the present invention is 2- (2H-benzotriazol-2-yl) -4-methyl-6- [2-methyl-3- [1,3,3,3-tetramethyl-1 - [( trimethylsilyl) oxy] disiloxa nyl] propyl] phenol (CAS no .: 155633-54-8) with the INCI name Drometrizole Trisiloxane, which is characterized by the chemical structural formula

is marked.

The UV-B filters can be oil-soluble or water-soluble. Advantageous oil-soluble UV-B filter substances are e.g. B .:

• - 3-benzylidene camphor derivatives, preferably 3- (4-methylbenzylidene) camphor, 3-benzy lidencampher;
• - 4-aminobenzoic acid derivatives, preferably 4- (dimethylamino) benzoic acid (2-ethyl hexyl ester, 4- (dimethylamino) benzoic acid amyl ester;
• - 2,4,6-trianilino- (p-carbo-2'-ethyl-1'-hexyloxy) -1,3,5-triazine;
• - Esters of benzalmalonic acid, preferably 4-methoxybenzalmalonic acid di (2-ethylhe xyl) ester;  
• - Esters of cinnamic acid, preferably 4-methoxycinnamic acid (2-ethylhexyl) ester, 4-methoxy zimtsäureisopentylester;
• Derivatives of benzophenone, preferably 2-hydroxy-4-methoxybenzophenone, 2- Hydroxy-4-methoxy-4'-methylbenzophenone, 2,2'-dihydroxy-4-methoxybenzophenone
• - As well as UV filters bound to polymers.

Advantageous water-soluble UV-B filter substances are e.g. B .:

• - Salts of 2-phenylbenzimidazole-5-sulfonic acid, such as its sodium, potassium or tri ethanolammonium salt, as well as the sulfonic acid itself;
• - Sulfonic acid derivatives of 3-benzylidene camphor, such as. B. 4- (2-Oxo-3-bornylidenme thyl) benzenesulfonic acid, 2-methyl-5- (2-oxo-3-bornylidenemethyl) sulfonic acid and their Salts.

Another light protection filter substance which can advantageously be used according to the invention is ethylhexyl-2-cyano-3,3-diphenylacrylate (octocrylene), which is available from BASF under the name Uvinul® N 539 and is distinguished by the following structure:

It can also be of considerable advantage to use polymer-bound or polymeric UV filters to use substances in preparations according to the present invention, esp in particular those as described in WO-A-92/20690.

Furthermore, it may be advantageous to add further UV-A and / or Incorporation of UV-B filters in cosmetic or dermatological preparations, for example as certain salicylic acid derivatives such as 4-isopropylbenzyl salicylate, 2-ethylhexyl salicylate (= Octyl salicylate), homomenthyl salicylate.  

The list of the UV filters mentioned, who are used for the purposes of the present invention of course, should not be limiting.

It is advantageous according to the invention to use the molar ratio of those mentioned under (a) and (b) Substances in the range from 10: 1 to 1:10, preferably 5: 1 to 1: 5, in particular preferably 2: 1 to 1: 2 to choose.

It is particularly advantageous according to the invention to use the one used according to the invention Active ingredient combination or cosmetic or topical dermatological preparations with an effective content of active ingredient combination used according to the invention for kos metallic or dermatological treatment or prophylaxis of unwanted skin stands to use.

According to the invention, preparations containing the active ingredient com contain binations, usual antioxidants are used.

The antioxidants are advantageously selected from the group consisting of amino acids (e.g. glycine, histidine, tyrosine, tryptophan) and their derivatives, imidazoles (e.g. urocanic acid) and their derivatives, peptides such as D, L-carnosine, D. -Carnosine, L-carnosine and their derivatives (e.g. anserine), carotenoids, carotenes (e.g. α-carotene, β-carotene, lycopene) and their derivatives, aurothioglucose, propylthiouracil and other thiols (e.g. Thioredoxin, glutathione, cysteine, cystine, cystamine and their glycosyl, N-acetyl, methyl, ethyl, propyl, amyl, butyl and lauryl, palmitoyl, oleyl, γ-linoleyl, cholesteryl and glyceryl esters) as well as their salts, dilauryl thiodipropionate, distearyl thiodipropionate, thiodipropionic acid and their derivatives (esters, ethers, peptides, lipids, nucleotides, nucleosides and salts) as well as sulfoximine compounds (e.g. buthioninsulfoximines, homocysteine sulfoximine, pentahioninsulfones, pentahioninsulfones, , Heptathioninsulfoximine) in very low tolerable doses (e.g. B. pmol to µmol / kg), also (metal) chelators (z. B. α-hydroxy fatty acids, palmitic acid, phy tic acid, lactoferrin), α-hydroxy acids (z. B. Citric acid, lactic acid, malic acid), Hu minic acid, bile acid, bile extracts, bilirubin, biliverdin, EDTA, EGTA and their derivatives, unsaturated fatty acids and their derivatives (e.g. γ-linolenic acid, linoleic acid, oleic acid), folic acid and their derivatives, alanine diacetic acid, flavonoids, polyphenols, catechins, vitamin C and derivatives (e.g. ascorbyl palmitate, Mg ascorbyl phosphate, ascorbyl acetate), toco pherols and derivatives (e.g. vitamin E acetate), as well as coniferyl benzoate of benzoin, rutinic acid and its derivatives, ferulic acid and its derivatives, butylated hydroxytoluene, butyl hydroxyanisole, nordihydroguayak resinic acid, nordihydroguajaretic acid, trihydroxybutyrophe der der, uric acid and its uric acid and uric acid and its uric acid Derivatives, zinc and its derivatives (e.g. ZnO, ZnSO ₄ ) and its derivatives (e.g. selenomethionine), stilbenes and their derivatives (e.g. stilbene oxide, trans-style) benoxid) and the derivatives suitable according to the invention (salts, esters, ethers, sugars, nucleotides, nucleosides, peptides and lipids) of these active substances.

The amount of antioxidants (one or more compounds) in the preparations preferably carries 0.001 to 30% by weight, particularly preferably 0.05-20% by weight, in particular special 1-10 wt .-%, based on the total weight of the preparation.

Prophylaxis or cosmetic or dermatological treatment with the inventor active ingredient used according to the invention or with the cosmetic or topical derma tological preparations with an effective content of used according to the invention Active ingredient takes place in the usual way, in such a way that the ver applied active ingredient or the cosmetic or topical dermatological preparations with an effective content of active ingredient used according to the invention on those affected skin areas is applied.

The active ingredient used according to the invention can advantageously be incorporated into conventional ones cosmetic and dermatological preparations, which are available in various forms can. So you can z. B. a solution, a water-in-oil (W / O) emulsion or of the oil-in-water (O / W) type, or a multiple emulsions, for example of the type Water-in-oil-in-water (W / O / W) or oil-in-water-in-oil (O / W / O), a hydrodispersion or lipodispersion, a gel, a solid stick or an aerosol.

Emulsions according to the invention in the sense of the present invention, for. B. in the form of a Crème, a lotion, a cosmetic milk are advantageous and contain z. B. fats, oils, Waxes and / or other fat bodies, as well as water and one or more emulsifiers, as are commonly used for such a type of formulation.

It is also possible and advantageous in the sense of the present invention, the inventive  active ingredient used in aqueous systems or surfactant preparations for cleaning the skin and hair.

It is of course known to the person skilled in the art that sophisticated cosmetic compositions tongues are usually not conceivable without the usual auxiliaries and additives. The invent Cosmetic preparations according to the invention can therefore contain cosmetic auxiliaries ten, as are usually used in such preparations, e.g. B. Conserve agents, bactericides, deodorising substances, antiperspirants, insects repellents, vitamins, anti-foaming agents, dyes, pigments with coloring effect, thickeners, softening substances, moisturizing and / or moisturizing substances, fats, oils, waxes or other common components of a cosmetic formulation such as alcohols, polyols, polymers, foam stabilizers, elec trolytes, organic solvents or silicone derivatives.

Mutatis mutandis apply corresponding requirements for the formulation of medical Preparations.

Contain medical topical compositions in the sense of the present invention usually one or more drugs in effective concentration. The simplicity for the sake of a clean distinction between cosmetic and medical application and corresponding products to the statutory provisions of the federal government republic of Germany (e.g. cosmetics regulation, food and pharmaceuticals law).

Cosmetic and dermatological preparations according to the invention advantageously also contain inorganic pigments based on metal oxides and / or other metal compounds which are sparingly soluble or insoluble in water, in particular the oxides of titanium (TiO ₂ ), zinc (ZnO), iron (e.g. Fe ₂ O ₃ ), Zirconium (ZrO ₂ ), silicon (SiO ₂ ), manganese (e.g. MnO), aluminum (Al ₂ O ₃ ), cerium (e.g. Ce ₂ O ₃ ), mixed oxides of the corresponding metals as well as mixtures from such oxides. Pigments based on TiO _{2 are} particularly preferred.

It is particularly advantageous in the sense of the present invention, although not necessarily when the inorganic pigments are in hydrophobic form, i.e. that is, they are upper  are treated to be water-repellent. This surface treatment can be in it stand that the pigments according to known methods with a thin hydropho ben layer.

One such method is, for example, that the hydrophobic surface layer according to a reaction

n TiO ₂ + m (RO) ₃ Si-R '→ n TiO ₂ (surface)

is produced. n and m are stoichiometric parameters to be used at will ter, R and R 'the desired organic radicals. For example, in analogy to DE-OS 33 14 742 hydrophobized pigments shown are advantageous.

Advantageous TiO ₂ pigments are available, for example, under the trade names MT 100 T from TAYCA, M 160 from Kemira and T 805 from De gussa.

Preparations according to the invention can, especially if crystalline or microcrystalline Solids, for example inorganic micropigments in the preparation according to the invention are to be incorporated, including anionic, nonionic and / or amphoteric Contain surfactants. Surfactants are amphiphilic substances that contain organic, non-polar substances Can dissolve water.

The hydrophilic parts of a surfactant molecule are mostly polar functional groups, for example -COO ^- , -OSO ₃ ^2- _, -SO ₃ ^- , while the hydrophobic parts generally represent non-polar hydrocarbon radicals. Surfactants are generally classified according to the type and charge of the hydrophilic part of the molecule. There are four groups:

• - anionic surfactants,
• - cationic surfactants,
• - amphoteric surfactants and
• - nonionic surfactants.

Anionic surfactants generally have carboxylate, sulfate or sulfonate groups as functional groups. In an aqueous solution they form negatively charged organic ions in an acidic or neutral environment. Cationic surfactants are characterized almost exclusively by the presence of a quaternary ammonium group. In aqueous solution they form positively charged organic ions in an acidic or neutral environment. Amphoteric surfactants contain both anionic and cationic groups and accordingly behave like anionic or cationic surfactants in aqueous solution depending on the pH. They have a positive charge in a strongly acidic environment and a negative charge in an alkaline environment. In the neutral pH range, however, they are zwitterionic, as the following example should illustrate:
RNH ₂ ⁺ CH ₂ CH ₂ COOH X ^- (at pH = 2): X ^- = any anion, e.g. B. Cl ^-
RNH ₂ ⁺ CH ₂ CH ₂ COO ^- (at pH = 7)
RNHCH ₂ CH ₂ COO ^- B ⁺ (at pH = 12): B ⁺ = any cation, e.g. B. Na ⁺ .

Polyether chains are typical of non-ionic surfactants. Non-ionic surfactants form in aqueous medium no ions.

A. Anionic surfactants

Anionic surfactants to be used advantageously are acylamino acids (and their salts), such as

• 1. Acylglutamates, for example sodium acylglutamate, di-TEA-palmitoylaspartate and Na trium caprylic / capric glutamate,
• 2. acyl peptides, for example palmitoyl-hydrolyzed milk protein, sodium cocoyl hydrolyzed soy protein and sodium / potassium cocoyl hydrolyzed collagen,
• 3. Sarcosinates, for example myristoyl sarcosin, TEA-lauroyl sarcosinate, sodium lauroyl sarcosinate and sodium cocoyl sarcosinate,
• 4. taurates, for example sodium lauroyl taurate and sodium methyl cocoyl taurate,
• 5. Acyl lactylate, lauroyl lactylate, caproyl lactylate
• 6. alaninates

Carboxylic acids and derivatives, such as

• 1. Carboxylic acids, for example lauric acid, aluminum stearate, magnesium alkanolate and zinc undecylenate,  
• 2. Ester carboxylic acids, for example calcium stearoyl lactylate, Laureth-6 citrate and Na trium PEG-4 lauramide carboxylate,
• 3. ether carboxylic acids, for example sodium laureth-13 carboxylate and sodium PEG-6 Cocamide carboxylate,

Phosphoric acid esters and salts, such as DEA-oleth-10-phosphate and dilaureth-4-phosphate,
Sulfonic acids and salts such as

• 1. acyl isethionates, e.g. B. sodium / ammonium cocoyl isethionate,
• 2. alkylarylsulfonates,
• 3. alkyl sulfonates, for example sodium cocosmonoglyceride sulfate, sodium C _12-14 olefin sulfonate, sodium lauryl sulfoacetate and magnesium PEG-3 cocamide sulfate,
• 4. Sulfosuccinates, for example dioctyl sodium sulfosuccinate, disodium laureth sulfosuc cinat, disodium lauryl sulfosuccinate and disodium undecylenamido MEA sulfosuccinate

such as
Sulfuric acid esters, such as

• 1. alkyl ether sulfate, for example sodium, ammonium, magnesium, MIPA, TIPA laureth sulfate, sodium myreth sulfate and sodium C _12-13 pareth sulfate,
• 2. Alkyl sulfates, for example sodium, ammonium and TEA lauryl sulfate.

B. Cationic surfactants

Cationic surfactants to be used advantageously

• 1. alkylamines,
• 2. Alkylimidazoles,
• 3. Ethoxylated amines and
• 4. Quaternary surfactants.
• 5. esterquats.

Quaternary surfactants contain at least one N atom that has 4 alkyl or aryl groups is covalently linked. Regardless of the pH value, this leads to a positive charge. Alkyl betaine, alkyl amidopropyl betaine and alkyl amidopropyl hydroxysulfain are advantageous. The cationic surfactants used according to the invention can furthermore preferably be selected are from the group of quaternary ammonium compounds, especially Ben  zyltrialkylammoniumchloride or bromides, such as benzyldimethylstea rylammonium chloride, further alkyltrialkylammonium salts, for example Ce tyltrimethylammonium chloride or bromide, alkyldimethylhydroxyethylammonium chloride or bromides, dialkyldimethylammonium chlorides or bromides, alkylamidethyltrimethylam monium ether sulfates, alkylpyridinium salts, for example lauryl or cetylpyrimidinium chloride, imidazoline derivatives and compounds with a cationic character such as amine oxides, for example alkyldimethylamine oxides or alkylaminoethyldimethylamine oxides. Advantageous especially cetyltrimethylammonium salts are to be used.

C. Amphoteric surfactants

Amphoteric surfactants to be used advantageously

• 1. acyl- / dialkylethylenediamine, for example sodium acylamphoacetate, disodium acyl amphodipropionate, disodium alkyl amphodiacetate, sodium acylamphohydroxypropyl sul fonate, disodium acyl amphodiacetate and sodium acyl amphopropionate,
• 2. N-alkylamino acids, for example aminopropylalkylglutamide, alkylaminopropion acid, sodium alkylimidodipropionate and lauroamphocarboxyglycinate.

D. Non-ionic surfactants

Non-ionic surfactants to be used advantageously

• 1. Alcohols,
• 2. alkanolamides, such as cocamides MEA / DEA / MIPA,
• 3. amine oxides, such as cocoamidopropylamine oxide,
• 4. Esters by esterification of carboxylic acids with ethylene oxide, glycerin, sorbitan or other alcohols,
• 5. ethers, for example ethoxylated / propoxylated alcohols, ethoxylated quarter propoxylated Esters, ethoxylated quarterly propoxylated glycerol esters, ethoxylated quarterly propoxylated cholesterol ne, ethoxylated / propoxylated triglyceride esters, ethoxylated propoxylated lanolin, ethoxylated / propoxylated polysiloxanes, propoxylated POE ethers and alkyl polyglycosi de such as lauryl glucoside, decyl glycoside and cocoglycoside.
• 6. sucrose esters, ether,
• 7. 7 polyglycerol esters, diglycerol esters, monoglycerol esters,
• 8. Methyl glucose esters, esters of hydroxy acids.

It is also advantageous to use a combination of anionic and / or ampho tere surfactants with one or more non-ionic surfactants.

The surface-active substance can have a concentration of between 1 and 95% by weight the preparations according to the invention are present, based on the total weight of the Preparations.

The lipid phase of the cosmetic or dermatological emulsions according to the invention can advantageously be selected from the following group of substances:

• - mineral oils, mineral waxes
• - Oils, such as triglycerides of capric or caprylic acid, as well as natural oils such. B. Castor oil;
• - Fats, waxes and other natural and synthetic fat bodies, preferably Esters of fatty acids with alcohols of low C number, e.g. B. with isopropanol, propylene glycol or glycerin, or esters of fatty alcohols with low C number alkanoic acids or with fatty acids;
• - alkyl benzoate;
• - silicone oils such as dimethylpolysiloxanes, diethylpolysiloxanes, diphenylpolysiloxanes like hybrid forms of it.

The oil phase of the emulsions of the present invention is advantageously selected from the Group of esters from saturated and / or unsaturated, branched and / or uns branched alkane carboxylic acids with a chain length of 3 to 30 carbon atoms and saturated and / or unsaturated, branched and / or unbranched alcohols of a chain length from 3 to 30 carbon atoms, from the group of esters from aromatic carboxylic acids and ge saturated and / or unsaturated, branched and / or unbranched alcohols of a ket length of 3 to 30 carbon atoms. Such ester oils can then advantageously be chosen from the group isopropyl myristate, isopropyl palmitate, isopropyl stearate, isopropyl oleate, n-Bu tyl stearate, n-hexyl laurate, n-decyl oleate, isooctyl stearate, isononyl stearate, isononylisononano at, 2-ethylhexyl palmitate, 2-ethylhexyl laurate, 2-hexyldecyl stearate, 2-octyldodecyl palmitate, Oleyl oleate, Oleylerucat, Erucyloleat, Erucylerucat as well as synthetic, semi-synthetic and natural mixtures of such esters, e.g. B. Jojoba oil.  

Furthermore, the oil phase can advantageously be selected from the group of branched and unbranched hydrocarbons and waxes, silicone oils, dialkyl ethers, Grup pe of saturated or unsaturated, branched or unbranched alcohols, and Fatty acid triglycerides, especially the triglycerol esters of saturated and / or unsaturated, branched and / or unbranched alkane carboxylic acids with a chain length of 8 to 24, ins special 12-18 carbon atoms. The fatty acid triglycerides can be advantageous, for example are selected from the group of synthetic, semi-synthetic and natural oils, z. B. olive oil, sunflower oil, soybean oil, peanut oil, rapeseed oil, almond oil, palm oil, coconut oil, Palm kernel oil and the like.

Any mixtures of such oil and wax components are also advantageous in the Sin ne use of the present invention. It may also be advantageous if Waxes, for example cetyl palmitate, are used as the sole lipid component of the oil phase Zen.

The oil phase is advantageously selected from the group consisting of 2-ethylhexyl isostearate, octyldodecanol, isotridecyl isononanoate, isoeicosane, 2-ethylhexyl cocoate, C _12-15 alkyl benzoate, caprylic Ca prinic acid triglyceride and dicaprylyl ether.

Mixtures of C _12-15 alkyl benzoate and 2-ethylhexyl isostearate, mixtures of C _12-15 alkyl benzoate and isotridecyl isononanoate and mixtures of C _12-15 alkyl benzoate, 2-ethyl hexyl isostearate and isotridecyl isononanoate are particularly advantageous.

Of the hydrocarbons, paraffin oil, squalane and squalene are advantageous in the sense of to use the present invention.

Advantageously, the oil phase can also have a content of cyclic or linear silicone oils or consist entirely of such oils, although it is preferred to use an additional content of other oil phase components in addition to the silicone oil or the silicone oils. Such silicones or silicone oils can be present as monomers, which are generally characterized by structural elements, as follows:

Linear silicones with a plurality of siloxyl units which can advantageously be used according to the invention are generally characterized by structural elements as follows:

wherein the silicon atoms can be substituted with the same or different alkyl radicals and / or aryl radicals, which are generally represented here by the radicals R ₁ -R ₄ (to say that the number of different radicals is not necessarily limited to up to 4). m can assume values of 2-200,000.

Cyclic silicones to be used advantageously according to the invention are generally characterized by structural elements as follows

wherein the silicon atoms can be substituted with the same or different alkyl radicals and / or aryl radicals, which are generally represented here by the radicals R ₁ -R ₄ (to say that the number of different radicals is not necessarily limited to up to 4). n can have values from 3/2 to 20. Broken values for n take into account that there may be odd numbers of siloxyl groups in the cycle.

Cyclomethicone (eg decamethylcyclopentasiloxane) is advantageous as according to the invention using silicone oil. But other silicone oils are also beneficial in the sense  to use the present invention, for example Undecamethylcyclotrisiloxan, Po lydimethylsiloxane, poly (methylphenylsiloxane), cetyldimethicone, behenoxydimethicone.

Mixtures of cyclomethicone and isotridecyl isononanoate and are also advantageous those made from cyclomethicone and 2-ethylhexyl isostearate.

However, it is also advantageous to use silicone oils of a constitution similar to that described above to choose neten compounds whose organic side chains derivatized, for example are polyethoxylated and / or polypropoxylated. These include, for example, polysiloxane polyalkyl polyether copolymers such as the cetyl dimethicone copolyol, the (cetyl dimethicone Copolyol (and) polyglyceryl-4-isostearate (and) hexyl laurate).

Mixtures of cyclomethicone and isotridecylisononano are also particularly advantageous at, from cyclomethicone and 2-ethylhexyl isostearate.

The aqueous phase of the preparations according to the invention may advantageously contain adheres alcohols, diols or polyols of low C number, and their ethers, preferably etha nol, isopropanol, propylene glycol, glycerin, ethylene glycol, ethylene glycol monoethyl or monobutyl ether, propylene glycol monomethyl, monoethyl or monobutyl ether, Diethy lenglykolmonomethyl- or -monoethylether and analogous products, furthermore low alcohols riger C number, z. As ethanol, isopropanol, 1,2-propanediol, glycerin and in particular a or several thickeners, which one or which can be chosen advantageously from the group silicon dioxide, aluminum silicates.

Preparations according to the invention in the form of emulsions contain in particular advantageously one or more hydrocolloids. These hydrocolloids can advantageously be chosen are from the group of gums, polysaccharides, cellulose derivatives, layered silicates, Polyacrylates and / or other polymers.

Preparations according to the invention which are present as hydrogels contain one or more Hydrocolloids. These hydrocolloids can advantageously be selected from the aforementioned group be chosen.  

Gums include plant or tree sap that harden in the air and resins form or extracts from aquatic plants. This group can be beneficial in the sense In the present invention, for example, gum arabic, carob are selected bread flour, tragacanth, karaya, guar gum, pectin, gellan gum, carrageenan, agar, algi ne, chondrus, xanthan gum.

Another advantage is the use of derivatized gums such. B. Hydroxypro pyl guar (Jaguar® HP 8).

Among the polysaccharides and derivatives are e.g. B. hyaluronic acid, chitin and Chitosan, chondroitin sulfates, starch and starch derivatives.

Among the cellulose derivatives are e.g. B. methyl cellulose, carboxymethyl cellulose, Hydroxyethyl cellulose, hydroxypropyl methyl cellulose.

Layered silicates contain naturally occurring and synthetic toners the like B. montmorillonite, bentonite, hectorite, laponite, magnesium aluminum silicates such as Veegum®. These can be used as such or in a modified form such as. B. Stearylalkonium hektorite.

Furthermore, silica gels can also advantageously be used.

Among the polyacrylates are e.g. B. Carbopol types from Goodrich (Carbopol 980, 981, 1382, 5984, 2984, EDT 2001 or Pemulen TR2).

Among the polymers are e.g. B. polyacrylamides (Seppigel 305), polyvinyl alcohols, PVP, PVP / VA copolymers, polyglycols.

Preparations according to the invention which are present as emulsions contain one or more other emulsifiers. These emulsifiers can advantageously be selected from the group the nonionic, anionic, cationic or amphoteric emulsifiers.

Among the nonionic emulsifiers are

• a) Partial fatty acid esters and fatty acid esters of polyhydric alcohols and their ethoxylated Derivatives (e.g. glyceryl monostearate, sorbitan stearate, glyceryl stearyl citrate, sucrose stearate)
• b) ethoxylated fatty alcohols and fatty acids
• c) ethoxylated fatty amines, fatty acid amides, fatty acid alkanolamides
• d) alkylphenol polyglycol ether (e.g. Triton X).

Among the anionic emulsifiers are

• a) soaps (e.g. sodium stearate)
• b) fatty alcohol sulfates
• c) mono-, di- and trialkylphosphonic acid esters and their ethoxylates.

Among the cationic emulsifiers are

• a) quaternary ammonium compounds with a long-chain aliphatic radical z. B. Distearyldimonium Chloride.

Among the amphoteric emulsifiers are

• a) Alkylaminoalkancarbonsäuren
• b) betaines, sulfobetaines
• c) imidazoline derivatives.

There are also naturally occurring emulsifiers, including beeswax, wool wax, Lecithin and sterols belong to it.

O / W emulsifiers can, for example, advantageously be selected from the group of polyethoxylated or polypropoxylated or polyethoxylated and polypropoxylated products, e.g. B .:

• - The fatty alcohol ethoxylates
• - the ethoxylated wool wax alcohols,
• the polyethylene glycol ether of the general formula RO - (- CH ₂ -CH ₂ -O-) _n -R ',
• the fatty acid ethoxylates of the general formula R-COO - (- CH ₂ -CH ₂ -O-) _n -H,
• the etherified fatty acid ethoxylates of the general formula R-COO - (- CH ₂ -CH ₂ -O-) _n -R ',
• the esterified fatty acid ethoxylates of the general formula R-COO - (- CH ₂ -CH ₂ -O-) _n -C (O) -R ',
• - The polyethylene glycol glycerol fatty acid ester
• - The ethoxylated sorbitan esters
• - the cholesterol ethoxylates
• - The ethoxylated triglycerides
• the alkyl ether carboxylic acids of the general formula RO - (- CH ₂ -CH ₂ -O-) _n -CH ₂ -COOH and n represent a number from 5 to 30,
• - the polyoxyethylene sorbitol fatty acid ester,
• - The alkyl ether sulfates of the general formula RO - (- CH ₂ -CH ₂ -O-) _n -SO ₃ -H
• the fatty alcohol propoxylates of the general formula RO - (- CH ₂ -CH (CH ₃ ) -O-) _n -H,
• the polypropylene glycol ether of the general formula RO - (- CH ₂ -CH (CH ₃ ) -O-) _n -R ',
• - the propoxylated wool wax alcohols,
• the etherified fatty acid propoxylates R-COO - (- CH ₂ -CH (CH ₃ ) -O-) _n -R ',
• the esterified fatty acid propoxylates of the general formula R-COO - (- CH ₂ -CH (CH ₃ ) -O-) _n - (O) -R ',
• the fatty acid propoxylates of the general formula R-COO - (- CH ₂ -CH (CH ₃ ) -O-) _n -H,
• - the polypropylene glycol glycerol fatty acid ester
• - The propoxylated sorbitan esters
• - the cholesterol propoxylates
• - the propoxylated triglycerides
• - The alkyl ether carboxylic acids of the general formula RO - (- CH ₂ -CH (CH ₃ ) O-) _n -CH ₂ -COOH
• - The alkyl ether sulfates or the acids underlying these sulfates of the general formula RO - (- CH ₂ -CH (CH ₃ ) -O-) _n -SO ₃ -H
• the fatty alcohol ethoxylates / propoxylates of the general formula ROX _n -Y _m -H,
• the polypropylene glycol ether of the general formula ROX _n -Y _m -R ',
• the etherified fatty acid propoxylates of the general formula R-COO-X _n -X _m -R ',
• - The fatty acid ethoxylates / propoxylates of the general formula R-COO-X _n -Y _m -H.

According to the invention, the polyethoxylated or po lypropoxylated or polyethoxylated and polypropoxylated O / W emulsifiers selected from the group of substances with HLB values of 11-18, very particularly advantageous with HLB values of 14.5-15.5, provided the O / W emulsifiers are saturated radicals R and R ' exhibit. Do the O / W emulsifiers have unsaturated radicals R and / or R ', or are Isoalkyl derivatives before, the preferred HLB value of such emulsifiers can also be lower or above.

It is advantageous to choose the fatty alcohol ethoxylates from the group of the ethoxylated stearyl alcohols, cetyl alcohols, cetyl stearyl alcohols (cetearyl alcohols). The following are particularly preferred:
Polyethylene glycol (13) stearyl ether (Steareth-13), polyethylene glycol (14) stearyl ether (Steareth-14), polyethylene glycol (15) stearyl ether (Steareth-15), polyethylene glycol (16) stearyl ether (Steareth-16), polyethylene glycol (17) stearyl ether (Steareth-17), polyethylene glycol (18) stearyl ether (Steareth-18), polyethylene glycol (19) stearyl ether (Steareth-19), polyethylene glycol (20) stearyl ether (Steareth-20),
Polyethylene glycol (12) isostearyl ether (isosteareth-12), polyethylene glycol (13) isostearyl ether (isosteareth-13), polyethylene glycol (14) isostearyl ether (isosteareth-14), polyethylene glycol (15) isostearyl ether (isosteareth-15), polyethylene glycol (16) isostearyl ether ( Isosteareth-16), polyethylene glycol (17) isostearyl ether (isosteareth-17), polyethylene glycol (18) isostearyl ether (isosteareth-18), polyethylene glycol (19) isostearyl ether (isosteareth-19), polyethylene glycol (20) isostearyl ether (isosteareth-20),
Polyethylene glycol (13) cetyl ether (ceteth-13), polyethylene glycol (14) cetyl ether (ceteth-14), polyethylene glycol (15) cetyl ether (ceteth-15), polyethylene glycol (16) cetyl ether (ceteth-16), polyethylene glycol (17) cetyl ether ( Ceteth-17), polyethylene glycol (18) cetyl ether (ceteth-18), polyethylene glycol (19) cetyl ether (ceteth-19), polyethylene glycol (20) cetyl ether (ceteth-20),
Polyethylene glycol (13) isocetyl ether (isoceteth-13), polyethylene glycol (14) isocetyl ether (isoceteth-14), polyethylene glycol (15) isocetyl ether (isoceteth-15), polyethylene glycol (16) isocetyl ether (isoceteth-16), polyethylene glycol (17) isocetyl ether (Isoceteth-17), polyethylene glycol (18) isocetyl ether (isoceteth-18), polyethylene glycol (19) isocetyl ether (isoceteth-19), polyethylene glycol (20) isocetyl ether (isoceteth-20),
Polyethylene glycol (12) oleyl ether (oleth-12), polyethylene glycol (13) oleyl ether (oleth-13), poly ethylene glycol (14) oleyl ether (oleth-14), polyethylene glycol (15) oleyl ether (oleth-15),
Polyethylene glycol (12) lauryl ether (Laureth-12), polyethylene glycol (12) isolauryl ether (Isolau reth-12).
Polyethylene glycol (13) cetylstearyl ether (ceteareth-13), polyethylene glycol (1 4) cetylstearyl ether (ceteareth-14), polyethylene glycol (15) cetylstearyl ether (ceteareth-15), polyethylene glycol (16) cetylstearyl ether (ceteareth-16), polyethylene glycol ) cetyl stearyl ether (Ceteareth-17), polyethylene glycol (18) cetyl stearyl ether (Ceteareth-18), polyethylene glycol (19) cetyl stearyl ether (Ceteareth-19), polyethylene glycol (20) cetyl stearyl ether (Ceteareth-20).

It is also advantageous to choose the fatty acid ethoxylates from the following group:
Polyethylene glycol (20) stearate, polyethylene glycol (21) stearate, polyethylene glycol (22) stearate, polyethylene glycol (23) stearate, polyethylene glycol (24) stearate, polyethylene glycol (25) stearate,
Polyethylene glycol (12) isostearate, polyethylene glycol (13) isostearate, polyethylene glycol (14) isostearate, polyethylene glycol (15) isostearate, polyethylene glycol (16) isostearate, polyethylene glycol (17) isostearate, polyethylene glycol (18) isostearate, polyethylene glycol (19) isostearate lenglycol (20) isostearate, polyethylene glycol (21) isostearate, polyethylene glycol (22) isostearate, polyethylene glycol (23) isostearate, polyethylene glycol (24) isostearate, polyethylene glycol (25) isostearate,
Polyethylene glycol (12) oleate, Polyethylene glycol (13) oleate, Polyethylene glycol (14) oleate, Poly ethylene glycol (15) oleate, Polyethylene glycol (16) oleate, Polyethylene glycol (17) oleate, Polyethylene glycol (18) oleate, Polyethylene glycol (19) oleate, polyethylene glycol (20) oleate.

As an ethoxylated alkyl ether carboxylic acid or its salt, this can be advantageous Sodium laureth-11 carboxylate can be used.

Sodium laureth 1-4 sulfate can advantageously be used as alkyl ether sulfate.

Polyethylene glycol (30) cholesteryl ether can advantageously be used as the ethoxylated cholesterol derivative be used. Polyethylene glycol (25) soyasterol has also proven itself.

Polyethylene glycol (60) evening primrose can advantageously be used as ethoxylated triglycerides Glycerides can be used (Evening Primrose = evening primrose).

Another advantage is the polyethylene glycol glycerol fatty acid esters from the group poly ethylene glycol (20) glyceryl laurate, polyethylene glycol (21) glyceryl laurate, polyethylene glycol (22) glyceryl laurate, polyethylene glycol (23) glyceryl laurate, polyethylene glycol (6) glyceryl caprate / capri nat, polyethylene glycol (20) glyceryl oleate, polyethylene glycol (20) glyceryl isostearate, polyethylene lenglycol (18) glyceryl oleate / cocoat to choose.

It is also favorable to use sorbitan esters from the group consisting of polyethylene glycol (20) sorbitanmo nolaurate, polyethylene glycol (20) sorbitan monostearate, polyethylene glycol (20) sorbitan monoiso stearate, polyethylene glycol (20) sorbitan monopalmitate, polyethylene glycol (20) sorbitan monool to choose at.

Advantageous W / O emulsifiers that can be used are: fatty alcohols with 8 to 30 Carbon atoms, monoglycerol esters saturated and / or unsaturated, branched and / or unbranched alkane carboxylic acids with a chain length of 8 to 24, in particular 12-18 carbon atoms, diglycerol esters saturated and / or unsaturated, branched and / or unbranched alkane carboxylic acids with a chain length of 8 to 24, in particular 12-18 C atoms, monoglycerol ethers saturated and / or unsaturated, branched and / or uns branched alcohols with a chain length of 8 to 24, in particular 12-18 carbon atoms, diglyce rinethers of saturated and / or unsaturated, branched and / or unbranched alcohols ner chain length of 8 to 24, in particular 12-18 carbon atoms, sown propylene glycol ester saturated and / or unsaturated, branched and / or unbranched alkane carboxylic acids Chain length of 8 to 24, in particular 12-18 C atoms and saturated sorbitan esters  and / or unsaturated, branched and / or unbranched alkane carboxylic acids of a ket length of 8 to 24, in particular 12-18 carbon atoms.

Particularly advantageous W / O emulsifiers are glyceryl monostearate, glyceryl monoiso stearate, glyceryl monomyristate, glyceryl monooleate, diglyceryl monostearate, diglyceryl mono isostearate, propylene glycol monostearate, propylene glycol monoisostearate, propylene glycol mono caprylate, propylene glycol monolaurate, sorbitan monoisostearate, sorbitan monolaurate, sorbitan monocaprylate, sorbitan monoisooleate, sucrose distearate, cetyl alcohol, stearyl alcohol, Arachidyl alcohol, behenyl alcohol, isobehenyl alcohol, selachyl alcohol, chimyl alcohol, poly ethylene glycol (2) stearyl ether (steareth-2), glyceryl monolaurate, glyceryl monocaprinate, glyce rylmonocaprylat.

The following examples are intended to illustrate but not limit the invention. The number Oil data relate to% by weight, unless stated otherwise.  

example 1

The components of the oil phase are combined and homogenized, then with the water phase combined and at a temperature of 80-85 ° C (i.e., in the phase inversion temp temperature range of the system), then cooled to room temperature (i.e. off the phase inversion temperature range of the system).  

Example 2

The components of the oil phase are combined and homogenized, then with the water phase combined and at a temperature of 80-85 ° C (i.e., in the phase inversion temp temperature range of the system), then cooled to room temperature (i.e. off the phase inversion temperature range of the system).  

Example 3

The components of the oil phase are combined and homogenized, then with the water phase combined and at a temperature of 80-85 ° C (i.e., in the phase inversion temp temperature range of the system), then cooled to room temperature (i.e. off the phase inversion temperature range of the system).  

Example 4

The components of the oil phase are combined and homogenized, then with the water phase combined and at a temperature of 80-85 ° C (i.e., in the phase inversion temp temperature range of the system), then cooled to room temperature (i.e. off the phase inversion temperature range of the system).  

Example 5

The components of the oil phase are combined and homogenized, then with the water phase combined and at a temperature of 80-85 ° C (i.e., in the phase inversion temp temperature range of the system), then cooled to room temperature (i.e. off the phase inversion temperature range of the system).  

Example 6

The respective components of the oil or water phase are combined, the two phases combined at 70-75 ° C and homogenized and then to room temperature cooled.  

Example 7

The respective components of the oil or water phase are combined, the two phases combined at 70-75 ° C and homogenized and then to room temperature cooled.  

Example 8

The respective components of the oil or water phase are combined, the two phases combined at 70-75 ° C and homogenized and then to room temperature cooled.  

Example 9

The respective components of the oil or water phase are combined, the two phases combined at 70-75 ° C and homogenized and then to room temperature cooled.  

Example 10

The respective components of the oil or water phase are combined, the two phases combined at 70-75 ° C and homogenized and then to room temperature cooled.  

Example 11

The respective components of the oil or water phase are combined, the two phases combined at 70-75 ° C and homogenized and then to room temperature cooled.  

Example 12

The respective components of the oil or water phase are combined, the two phases combined at 70-75 ° C and homogenized and then to room temperature cooled.  

Example 13

The respective components of the oil or water phase are combined, the two phases combined at 70-75 ° C and homogenized and then to room temperature cooled.  

Example 14

The respective components of the oil or water phase are combined, the two phases combined at 70-75 ° C and homogenized and then to room temperature cooled.  

Example 15

The respective components of the oil or water phase are combined, the two phases combined at 70-75 ° C and homogenized and then to room temperature cooled.  

Example 16

The respective components of the oil or water phase are combined, the two phases combined at 70-75 ° C and homogenized and then to room temperature cooled.  

Example 17

The respective components of the oil or water phase are combined, the two phases combined at 70-75 ° C and homogenized and then to room temperature cooled.  

Example 18

The respective components of the oil or water phase are combined, the two phases combined at 70-75 ° C and homogenized and then to room temperature cooled.  

Example 19

The respective components of the oil or water phase are combined, the two phases combined at 70-75 ° C and homogenized and then to room temperature cooled.  

Example 20

The respective components of the oil or water phase are combined, the two phases combined at 70-75 ° C and homogenized and then to room temperature cooled.  

Example 21

The respective components of the oil or water phase are combined, the two phases combined at 70-75 ° C and homogenized and then to room temperature cooled.  

Example 22

The respective components of the oil or water phase are combined, the two phases combined at 70-75 ° C and homogenized and then to room temperature cooled.  

Example 23

The respective components of the oil or water phase are combined, the two phases combined at 70-75 ° C and homogenized and then to room temperature cooled.  

Example 24

The respective components of the oil or water phase are combined, the two phases combined at 70-75 ° C and homogenized and then to room temperature cooled.  

Example 25

The respective components of the oil or water phase are combined, the two phases combined at 70-75 ° C and homogenized and then to room temperature cooled.  

Example 26

The respective components of the oil or water phase are combined, the two phases combined at 70-75 ° C and homogenized and then to room temperature cooled.

Claims (3)

1. Use of active ingredient combinations

• a) α-lipoic acid and
• b) one or more dermatologically compatible substances which produce light absorption in the UV-A range and / or UV-B range,

for the prophylaxis and treatment of inflammatory skin conditions - including atopic eczema - and / or for skin protection for sensitive, determined dry skin. 2. Use according to claim 1, characterized in that it 0.001-10 wt .-% α-Lipoic acid, based on the total weight of the preparations. 3. Use according to claim 1, characterized in that they egg 0.001-10 wt .-% contain one or more substances, selected from the group of dermatologically ver inert substances that show light absorption in the UV-A range and / or UV-B range.